The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.

Peter Johansson(Sahlgrenska University Hospital), Björn Andréasson(NU Hospital Group), Carina Wasslavik(Sahlgrenska University Hospital), Anne Ricksten(Sahlgrenska University Hospital), Berit Johansson(Södra Älvsborg Hospital)
PubMed
October 1, 2004
Cited by 3

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
|Journal of Clinical Oncology|2012|461
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
|Blood|2011|340
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
|Journal of Clinical Oncology|2011|244
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
|Blood|2014|153